While clearly lagging behind their US counterparts, European biotechnology companies and medtech firms across all stages of development can still attract significant venture capital if they are innovative enough.
That is what Olivier Litzka of Edmond De Rothschild Investment Partners (EdRIP) told Scrip as the Paris-based finance house unveiled...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?